Abstract 440P
Background
In this study the risk scoring algorithm is evaluated to see the ability of the scoring systems to accurately identify patients deemed to be high risk for CINV.
Methods
Patients who were receiving first chemotherapy regime at our center were included in the study after due informed consenting and Ethics committee approval. Patients were followed for 5-days after chemotherapy by either in person questioning or telephone call. All patients received standard anti-emetic prophylaxis at discretion of treating physician. Before each cycle of chemotherapy, acute and delayed CINV scoring systems were used to stratify patients into low- and high-risk groups. Logistic regression modelling was then applied to compare the risk for grade 2 or greater CINV between patients considered to be at high and at low risk. The external validity of each system was also assessed using an area under the receiver operating characteristic curve (AUROC) analysis.
Results
CINV outcomes data was collected from 128 patients during 356 cycles of chemotherapy. The incidence of delayed CINV was 76.4% respectively. Major predictors for CINV included younger patient age, earlier cycles of chemotherapy, previous history of morning sickness, and prior emetic episodes after chemotherapy. The delayed scoring system had good predictive accuracy when applied to the external validation sample (delayed—AUROC: 0.75; 95% confidence interval: 0.70 to 0.80). Patients identified by the scoring systems to be at high risk were 3.8 (p = 0.001) times more likely to develop grade 2 or greater delayed CINV.
Conclusions
Our study demonstrates current Patient risk scoring systems are able to accurately identify patients at high risk for delayed CINV and can be used to augment current antiemetic regimes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vinayak V Maka.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract